Central Research Institute Vision
Central Research Institute Vision
-
Strengthening research competitiveness through
-
R&D VISION 2030
A research institute with NCE drug
discovery and global R&D capabilities.Key Focus Areas
NCEs; IMDs; and first generics
supported by in-house bioequivalence
(BE) studies. -
focus and prioritization.
Kukje Pharma's R&D Projects
for Global Innovative
New Drug Development
The Kukje Pharma Central Research Institute conducts
ongoing R&D in prioritized research areas and key disease indications,
while strengthening strategic R&D networks
with leading institutions to advance globally competitive innovation.
Synthetic New Drugs
| Projects | Indication | Feature | Development stage |
|---|---|---|---|
| KJ16002 | anti-inflammatory treatment | development of an anti-inflammatory treatment via mPGES-1 inhibition | |
| KJ2201 | vascular disease treatment | development of a novel-mechanism antiplatelet therapeutic designed to reduce side effects associated with marketed products |
Incrementally Modified Drugs (IMDs)
| Projects | Indication | Feature | Development stage |
|---|---|---|---|
| KJ13001 | anti-infective treatment | development of a high-dose formulation | |
| KJ16001 (KSR-001) |
ophthalmic disease treatment | development of a dry-eye treatment | |
| KJ14002 (TFC-003) |
ophthalmic disease treatment | development of a triple-combination treatment for glaucoma | |
| KJ14004 (HCS-001) |
ophthalmic disease treatment | : development of a dry-eye treatment (combination product) |